Promising Effectiveness of Efti and KEYTRUDA in Head and Neck Cancer
Recently, key follow-up results from a pivotal clinical trial created quite a stir at a major international medical conference. This trial, known as TACTI-003, examined the use of eftilagimod alpha (commonly referred to as efti), developed by Immutep, in combination with KEYTRUDA, produced by MSD, as a treatment option for patients battling recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Highlights from the TACTI-003 Trial
These important findings, previously discussed on multiple occasions, were underscored in a Proffered Paper presentation at the ESMO Congress 2024. Lead researcher Claus Kristensen shared that combining efti with KEYTRUDA resulted in a noteworthy objective response rate (ORR) of 32.8% among patients showing any PD-L1 expression, a significant improvement over the 26.7% ORR seen with KEYTRUDA alone.
Elevated Response Rates in Patients with High PD-L1 Expression
A closer look at the data revealed even more promising results for patients with high PD-L1 expression (CPS ?20), who showed an impressive ORR of 31.0%. This is particularly hopeful for a group of patients who typically have limited treatment options. The combination of efti yielded even better results, achieving a complete response rate of 6.9% as opposed to 3.7% for those receiving KEYTRUDA as a single agent.
Long-lasting Treatment Response
One of the notable advantages of efti is the durability it provides in patient responses. The median duration of response (DOR) was recorded at 17.5 months for those receiving the combination treatment, a favorable figure when compared to historical data. Generally, other combinations deliver much shorter DOR periods, typically around 6 to 7 months when paired with chemotherapy.
Biological Activity and Immune Response
An important finding from this trial is the significant increase in the absolute lymphocyte count (ALC) in patients treated with efti alongside KEYTRUDA. This heightened immune response is recognized as a vital biomarker, indicating enhanced biological activity in patients undergoing this combination therapy.
Favorable Safety Profile
In terms of safety, the combination continues to uphold a good safety profile, with no new safety concerns emerging. The rates of treatment interruption due to adverse events were similar across both treatment groups, highlighting promising tolerability. Moreover, the combination therapy presents a risk profile that is comparable to KEYTRUDA alone, with only minor injection site reactions anticipated due to efti's administration method.
Looking to the Future and Regulatory Engagement
As Immutep moves forward, engaging with regulatory agencies to determine the next steps based on this compelling data is essential. The company expects to have evidence for overall survival available by 2025, which will inform future treatment strategies in this challenging field.
The Future of Oncology and Immutep
Immutep remains dedicated to transforming cancer treatment through its innovative development of efti. By enhancing the immune response in conjunction with immune checkpoint inhibitors like KEYTRUDA, the company aims to reshape the treatment landscape for patients with significant unmet medical needs. Their ongoing commitment to research and collaboration with regulatory bodies is expected to lead to new therapeutic alternatives that genuinely enhance patient outcomes.
Trials and studies like these not only contribute to the existing body of knowledge but also offer hope to patients and healthcare professionals alike. The journey of efti highlights the significance of continuous research and the pursuit of innovative treatment pathways in the ongoing fight against cancer.
Frequently Asked Questions
What is the main focus of the TACTI-003 trial?
The TACTI-003 trial investigates the effectiveness and safety of eftilagimod alpha (efti) when combined with KEYTRUDA as a first-line treatment for recurrent or metastatic head and neck cancer.
What were the reported objective response rates (ORR) for efti with KEYTRUDA?
The combination therapy achieved an ORR of 32.8% in patients with any PD-L1 expression and 31.0% in those with high PD-L1 expression (CPS ?20).
How does the duration of response compare to other treatments?
The median duration of response for the efti and KEYTRUDA combination was 17.5 months, which is notably longer than the usual 6 to 7 months observed with traditional chemotherapy combinations.
What safety considerations were noted in the trial?
The trial identified no new safety concerns for the combination, and the rates of treatment discontinuation due to adverse events were low and consistent across both combination and single-agent therapies.
How does this research impact future cancer treatment developments?
This research marks significant advancements in immunotherapy combinations that enhance treatment efficacy and safety, potentially expanding treatment options for patients facing various cancers.
